Results from a recent study indicate that many myeloma patients are like­ly to suffer im­paired cog­ni­tive func­tion after their initial multiple mye­lo­ma therapy, and stem cell trans­planta­tion often causes further im­pairment.

Nearly half of the patients in the study had cog­ni­tive im­pair­ment, often referred to as ‘chemo brain,’ after receiving initial anti-myeloma therapy.  Half of the patients experienced further im­pair­ment of cog­ni­tive function at one month and again at three months following autologous (own) stem cell trans­planta­tion.

The study authors explain that the most common signs of cog­ni­tive im­pair­ment were problems with …